Lv0
0 积分 2021-11-13 加入
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B
8个月前
已完结
Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA)
8个月前
已完结
The role of HBV cccDNA in occult hepatitis B virus infection
8个月前
已完结
Epigenetic regulation of covalently closed circular DNA minichromosome in hepatitis B virus infection
8个月前
已完结
Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo
8个月前
已完结
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
8个月前
已完结
Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics
8个月前
已完结
New strategies for the treatment of chronic hepatitis B
8个月前
已完结
Mapping the Interactions of HBV cccDNA with Host Factors
8个月前
已完结
皖公网安备34019202002308
